Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

Market Cap	11.57B +117.3%
Revenue (ttm)	1.33B -1.4%
Net Income	283.25M +18.9%
EPS	1.63 +19.9%
Shares Out	174.35M
PE Ratio	40.72
Forward PE	38.15
Dividend	0.43 (0.65%)
Ex-Dividend Date	Jun 11, 2025

Volume	4,040,301
Average Volume	2,076,811
Open	62.01
Previous Close	62.01
Day's Range	61.00 - 68.51
52-Week Range	29.89 - 73.66
Beta	0.22
RSI	61.56
Earnings Date	Apr 22, 2026

About SHA:688513

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricarace...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 1,522
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688513

Financial Performance

In 2025, SHA:688513's revenue was 1.33 billion, a decrease of -1.36% compared to the previous year's 1.35 billion. Earnings were 283.25 million, an increase of 18.89%.